Serum Institute, Bharat Biotech to begin trial of intranasal COVID-19 vaccine soon: Health Minister Harsh Vardhan

By: |
October 18, 2020 9:54 PM

Dr Harsh Vardhan said the late stage trial generally involves thousands of participants, sometimes 30,000 to 40,000.

Some experts fear vaccines may not even meet the 50% efficacy threshold that the WHO has advised for vaccine candidates qualifying for use.Pfizer vaccine requires to be stored at minus 70 degrees unlike other vaccine candidates.

Serum Institute of India and Bharat Biotech are expected to pursue late stage clinical trials of intranasal COVID-19 vaccines in the coming months once they receive regulatory approval, India’s health minister said on Sunday.

Dr Harsh Vardhan said the late stage trial generally involves thousands of participants, sometimes 30,000 to 40,000.

Of the vaccines currently in Phase 3 trials, all are administered by injection, according to the World Health Organization (WHO).

On Saturday, India’s Dr Reddy’s Laboratories Ltd and the Russian Direct Investment Fund (RDIF) said they have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine.

India’s coronavirus infections rose by another 61,871 over the past 24 hours, data released on Sunday showed, although the health ministry said it is seeing a trend of steadily declining active cases.

The Indian Council of Medical Research (ICMR) said it will revisit its protocol for COVID-19 treatment after the WHO found some of the commonly used drugs, including remdesivir, had little or no impact on a patient’s chances of surviving, local media reported earlier on Sunday.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Coronavirus in India: 86.25% new COVID cases in 6 states, says govt
2Covid-19: Too much data — is it good or bad? Here’s what MIT study says
3Natco’s marketing partner gets USFDA nod for cancer treatment drug